Mid
L
LGNDAI Stock Diagnostic Report
Ligand forecasts $9-$9.50 adjusted EPS in 2026 as XOMA deal adds about $0.50 in 2H 2026
Ligand Pharmaceuticals expects to contribute approximately $0.50 to adjusted EPS in the second half of 2026 due to the XOMA transaction, and has provided an adjusted EPS outlook of $9-$9.50 for 2026.
View Source Article ↗AI CATALYST SCORE80 / 100Score computed by Sentinel V12
REFERENCE PRICE$308.07Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
The adjusted EPS guidance for 2026 is projected to be $9 to $9.50, indicating expectations for improved profitability, with an estimated contribution of approximately $0.50 from the XOMA deal in the second half of 2026, which will act as a substantial earnings contributor.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The announcement of an upward revision to its own financial guidance can be interpreted as a signal of sustained growth based on internal business plans rather than external events.